US · Healthcare · Biotechnology
EPS came in at 1.21 against a street estimate of 1.44 — a miss of 16.0%.
Analysts rate Alnylam Pharmaceuticals Inc a buy (22 buy, 8 hold, 0 sell out of 30) with an average price target of $371.35.
MIXED AMVUTRA hit $1B+ quarterly revenue in rare disease launch, but Alnylam cut full-year guidance $200M citing normalized second-line demand. First-line momentum and favorable competitor exits support confidence in 2030 goals. Q2 2026 New Ben Pharma partnership announced for exclusive AMVUTRA commercialization rights in Mainland China and Hong Kong, subject to regulatory approval. Europe growing modestly due to price adjustments ahead of tafamidis generics. Analysts pressed on guidance cut mechanics, combo therapy payer pushback post-CARDIO-TTRansform, and TRITON-CM protocol flexibility. Management emphasized first-line durability, intact access, and confidence in nucrisiran's superior knockdown profile. 2026-07-30…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 10.90% |
| Capital World Investors | 8.33% |
| BlackRock Inc | 7.81% |
| Capital Research Global Investors | 7.29% |
| Vanguard Portfolio Management, LLC | 4.85% |
| JPMorgan Chase & Co | 4.73% |
| Vanguard Capital Management, LLC | 4.44% |
| T. Rowe Price Investment Management,Inc. | 3.88% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 ALNYLAM PHARMACEUTICALS, INC. – FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Net product revenues (Q2 2026): $1,172,109 tho | 2026-07-30 |
| Results announced · Q3 2026 ALNYLAM PHARMACEUTICALS Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Global Net Product Revenues: $1,172 million (74% growth vs Q2 2025) • To | 2026-07-30 |
| Board / officer change · Q2 2026 ALNYLAM PHARMACEUTICALS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Board expanded from 10 to 11 directors effective June 1, 2026 • 133,427,910 shar | 2026-05-27 |
| Quarterly report · Q1 2026 ALNYLAM PHARMACEUTICALS, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues (Q1 2026): $1,167.2 million vs. $594.2 million (Q1 2025) — in | 2026-04-30 |
| Results announced · Q2 2026 ALNYLAM PHARMACEUTICALS Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q1 2026 total net product revenues: $1,036 million (121% growth vs. Q1 2025) • Q | 2026-04-30 |
| Proxy statement · Q2 2026 ALNYLAM PHARMACEUTICALS (ALNY) – 2026 PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect three Class I directors to serve until 2029: | 2026-04-06 |
| Board / officer change · Q1 2026 ALNYLAM PHARMACEUTICALS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • CEO Yvonne Greenstreet granted special performance-based equity award on March 2 | 2026-03-04 |
| Annual report FY2025 ALNYLAM PHARMACEUTICALS, INC. — 10-K SUMMARY HEADLINE NUMBERS • Market capitalization: approximately $42.63 billion as of June 30, 2025 • Shares out | 2026-02-12 |
Readable in the app.
| Announcement | Date |
|---|---|
| 2025 preliminary results and 2026 combined net product revenue guidance provided Alnylam Pharmaceuticals announced strong 2025 preliminary revenues and unveiled a new five-year strategic plan called 'Alnylam 2030.' The company reported approximately $2.987 billion in ful | 2026-01-12 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Alnylam Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.